ISRCTN75169762已完成不适用
Mepolizumab and exacerbation frequency in refractory eosinophilic asthma: a randomised, double blind, placebo controlled trial
niversity Hospitals of Leicester NHS Trust (UK)0 个研究点目标入组 60 人开始时间: 2005年8月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. 60 participants meeting American thoracic criteria for refractory asthma
- •2. On intensive corticosteroid therapy - either oral and/or inhaled
- •3. A history of two or more exacerbations of asthma requiring oral corticosteroid rescue therapy in one year
- •4. Evidence of persistent eosinophilic inflammation in sputum - sputum eosinophils greater than 3% of total cell count
排除标准
- •1. Participants who do not meet American Thoracic Society criteria for severe asthma
- •2. Participants who have not demonstrated evidence of persistent eosinophilic airway inflammation (sputum eosinophil counts of greater than or equal to 3% of total cell count
- •3. Partcipants who are current smokers or who have a cumulative smoking history of greater than 15 pack years
- •4. Participants with significant co morbidity - including other symptomatic respiratory diagnoses, evidence of recurrent bacterial respiratory tract infections (greater than or equal to 2 per year), symptomatic ischaemic heart disease and mental health or other conditions that interfere with participant compliance with the study
- •5. Pregnant females or women of child bearing age not practising effective contraception during the study
研究者
相似试验
进行中（未招募）
1 期
Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial.Refractory Eosinophilic Asthma.EUCTR2005-001932-61-GBniversity Hospitals of Leicester60
已完成
不适用
Exploring Asthma Exacerbations in Mepolizumab Treated PatientsAsthma BrittleNCT03324230Queen's University, Belfast146
招募中
不适用
Mepolizumab for treatment of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - A pilot studyDRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndromeInflammatory and Immune System - AllergiesACTRN12621001333808St Vincent's Hospital, Sydney8
撤回
不适用
The consequences of mepolizumab-mediated depletion of eosinophils on adaptive and innate immune responses.adaptive and innate defenseimmune system1000170810006436NL-OMON45798Academisch Medisch Centrum100
进行中（未招募）
1 期
Pembrolizumab in progressive multifocal leukoencephalopathy (PML) in immunocompromised patients without HIV infection (PENALTY)Immunocompromised patients with PML (with an underlying cause of immunosuppression hardly reversible, i.e. not the patients with HIV nor those receiving biologics for chronic inflammatory diseases).MedDRA version: 20.1Level: PTClassification code: 10036807Term: Progressive multifocal leukoencephalopathy Class: 100000004862MedDRA version: 20.0Level: SOCClassification code: 10021881Term: Infections and infestations Class: 1CTIS2023-503520-31-00Assistance Publique Hopitaux De Paris33